

Supplementary Materials

Plasma-Induced Oxidation Products of (–)-Epigallocatechin Gallate with Digestive Enzymes Inhibitory Effects

Gyeong Han Jeong and Tae Hoon Kim *

Department of Food Science and Biotechnology, Daegu University, Gyeongsan
38453, Korea; jkh4598@hanmail.net

* Correspondence: skyey7@daegu.ac.kr; Tel.: +82-53-850-6533

Contents

Figure S1. Isolation procedure of plasma irradiated EGCG in aqueous solution.

Figure S2. HPLC chromatograms of isolated compounds **1-3**.

Figure S3. ^1H NMR spectrum of compound **1** in CD_3OD .

Figure S4. ^{13}C NMR spectrum of compound **1** in CD_3OD .

Figure S5. HSQC spectrum of compound **1** in CD_3OD .

Figure S6. HMBC spectrum of compound **1** in CD_3OD .

Figure S7. FABMS spectrum of compound **1**.

Figure S8. ^1H NMR spectrum of compound **2** in CD_3OD .

Figure S9. ^{13}C NMR spectrum of compound **2** in CD_3OD .

Figure S10. FABMS spectrum of compound **2**.

Figure S11. ^1H NMR spectrum of compound **3** in CD_3OD .

Figure S12. Calibration curve of EGCG and oxidation products **1-3**.

Figure S13. Chemical structures of isolated compounds **1-3**.





Figure S1. Isolation procedure of plasma irradiated EGCG in aqueous solution.






Figure S2. HPLC chromatograms of isolated compounds **1-3**.






Figure S3. ^1H NMR spectrum of compound **1** in CD_3OD .






Figure S8. ^1H NMR spectrum of compound **2** in CD_3OD .




Figure S9. ^{13}C NMR spectrum of compound **2** in CD_3OD .

[Mass Spectrum]
 Data : FAB530 Date : 15-Jan-2020 17:25
 Instrument : MStation
 Sample : WEP-05
 Note : m-NBA
 Inlet : Direct Ion Mode : FAB-
 Spectrum Type : Normal Ion [MF-Linear]
 RT : 2.00 min Scan# : (11,13) Temp : 3276.7 deg.C
 BP : m/z 153 Int. : 481.88 (5052906)
 Output m/z range : 10 to 700 Out Level : 0.00 %




Figure S10. FABMS spectrum of compound **2**.





Figure S11. ¹H NMR spectrum of compound **3** in CD₃OD.

EGCG quinone dimer A (**1**): Brown amorphous powder, $[\alpha]_D^{25}$ -62.3 (*c* 0.1, MeOH), FABMS *m/z* 929 [M-H]⁻, ¹H NMR (500 MHz, CD₃OD): δ 6.92 (4H, s, H-2'', 6''), 6.54 (2H, d, *J* = 1.0 Hz, H-6'), 6.03 (2H, d, *J* = 2.0 Hz, H-8), 5.99 (2H, d, *J* = 2.0 Hz, H-6), 5.68 (2H, br dd, *J* = 4.0, 1.0 Hz, H-3), 4.56 (2H, br s, H-2), 3.22 (2H, br s, H-2'), 2.95 (2H, m, H-4), 2.93 (2H, m, H-4), ¹³C NMR (125 MHz, CD₃OD): δ 196.5 (C-5'), 165.9 (C-7''), 156.6 (C-7), 156.5 (C-9), 155.8 (C-1'), 154.4 (C-5), 144.9 (C-3'', 5''), 138.5 (C-4''), 126.7 (C-6'), 119.6 (C-1''), 108.9 (C-2''),

6"), 103.7 (C-3'), 97.7 (C-10), 95.6 (C-8), 94.4 (C-6), 84.7 (C-4'), 75.9 (C-2), 63.8 (C-3), 59.2 (C-2'), 25.2 (C-4).

Theacitrinin A (**2**): Brown amorphous powder, $[\alpha]_D^{25} +104.8$ (*c* 0.1, MeOH), FABMS m/z 579 $[M-H]^-$, 1H NMR (500 MHz, CD₃OD): δ 6.95 (2H, s, H-2', 6'), 6.71 (1H, s, H-f), 6.05 (1H, d, $J = 2.0$ Hz, H-8), 5.98 (1H, d, $J = 2.0$ Hz, H-6), 5.85 (1H, br s, H-c), 5.73 (1H, m, H-3), 5.23 (1H, br s, H-2), 4.35 (1H, s, H-e), 2.91 (1H, dd, $J = 17.0$, 4.0 Hz, H-4), 2.80 (1H, dd, $J = 17.0$, 1.0 Hz, H-4), ^{13}C NMR (125 MHz, CD₃OD): δ 200.1 (C-b), 193.9 (C-l), 174.0 (C-d), 166.0 (C-7'), 157.0 (C-g), 156.9 (C-5), 156.1 (C-7), 155.0 (C-9), 148.2 (C-3', 5'), 145.1 (C-i), 143.0 (C-k), 138.9 (C-4'), 134.0 (C-h), 125.0 (C-c), 122.0 (C-1'), 115.0 (C-j), 108.8 (C-2', 6'), 106.1 (C-f), 100.4 (C-10), 97.2 (C-6), 95.9 (C-8), 84.8 (C-a), 73.1 (C-2), 63.0 (C-3), 54.8 (C-e), 29.0 (C-4).

Gallic acid (**3**): White amorphous powder, 1H NMR (500 MHz, CD₃OD): δ 7.08 (2H, s, H-2, 6).



Compounds	t_R (min)	UV λ_{max} (nm)	$[M-H]^-$	Regression equation ^a	Linear range
				($Y=aX+b, R^2$)	(µg/mL)
(-)-EGCG	15.6	224, 280	457	$Y = 5126.9X + 30580, 0.9997$	500-31.25
1	15.0	276	929	$Y = 3691.1X + 10817, 0.999$	500-31.25
2	16.2	277, 345	579	$Y = 5265.4X - 4737, 0.9997$	500-31.25
3	8.0	214, 268	169	$Y = 15629X - 109172, 0.9994$	500-31.25

^a Y = peak area and X = concentration.

Figure S12. Calibration curve of EGCG and oxidation products **1-3**.




Figure S13. Chemical structures of isolated compounds 1-3.